Clinical Trial Update: A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability study of topical PAT-001 in congenital ichthyosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Ichthyosis

Drugs mentioned

• PAT-001

Snippet

Sponsor: Patagonia Pharmaceuticals, LLC | Conditions: Congenital Ichthyosis | Phase 2 | Status: COMPLETED | Results posted: 2021-09-02